

NANOVIRICIDES WILL RETURN TO \$3-\$5 AS SOON AS THE CORONAVIRUS NEWSFLOW FADES

February 3, 2020



RESEARCH SUMMARY

Our research suggests that NanoViricides (NNVC) is unable to even attempt to create a coronavirus vaccine or treatment.

On 1/24/20, NNVC sold 2.85M shares at \$3 apiece, which is about 20% of the current share price.

NNVC has told investors it would create a vaccine for other epidemics in the past, like Zika, but those went nowhere.

NNVC has basically the same pipeline of preclinical drugs that it had since 2008.

On 1/30/20, NNVC announced it is working on a coronavirus treatment, however it states that it has not been offered any collaborative funding.

Our research suggests that NanoViricides (NNVC) is unable to even attempt to create a coronavirus vaccine or treatment.

On 1/24/20, NNVC sold 2.85M shares at \$3 apiece, which is about 20% of the current share price.

NNVC has told investors it would create a vaccine for other epidemics in the past, like Zika, but those went nowhere.

NNVC has basically the same pipeline of preclinical drugs that it had since 2008.

On 1/30/20, NNVC announced it is working on a coronavirus treatment, however it states that it has not been offered any collaborative funding.



Independent institutional-grade research focused on identifying asymmetric risks in small and micro-cap equities.

LEGAL DISCLAIMER

As of the publication date of our reports, White Diamond Research, along with its clients, affiliates, and related entities, may have a short position in the securities discussed and stand to realize significant gains in the event that the price of the stock declines. Use White Diamond Research at your own risk. You should do your own research and due diligence before making any investment decision. No information contained in our reports should be interpreted as financial advice.

© 2026 White Diamond Research LLC

